The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November ...

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, reports RTBF ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

European regulators initially said in July that the drug's benefits did not outweigh its risks.View on euronews ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...